Mycobacterium avium complex pulmonary disease in patient without HIV infection

Chest

Volumn 126, Issue 2, 2004, Pages 566-581

  Field, Stephen K ^a,b   Fisher, Dina ^a   Cowie, Robert L ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b 3330 Hospital Dr NW   (Canada)

Author keywords

Bronchiectasis; Clarithromycin; Ethambutol; Macrolides; Mycobacterium avium; Mycobacterium intracellulare; Nontuberculous mycobacteria; Rifabutin rifampin

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; FRESH WATER; GAMMA INTERFERON; HOT WATER; ISONIAZID; MINOCYCLINE; OFLOXACIN; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; SEA WATER; STREPTOMYCIN;

BRONCHIECTASIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG DISEASE; MEDICAL LITERATURE; MEDICAL SOCIETY; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL; RELAPSE; REVIEW; SKIN TEST; THORAX DEFORMITY; THORAX RADIOGRAPHY;

EID: 4143146413     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.2.566     Document Type: Review

References (181)

1. Edwards LB, Palmer CE. Isolation of "atypical" mycobacteria from healthy persons. Am Rev Respir Dis 1959; 80:747-749
2. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321:863-868
3. Tsukumura M. Background factors for casual isolation of Mycobacterium intracellulare from sputum of patients with tuberculosis. Am Rev Respir Dis 1973; 108:679-683
4. Tsukumura M. Clinical significance of casual isolation of acid-fast organisms from sputum of tuberculous patients. Am Rev Respir Dis 1973; 108:1429-1430
5. Horsburgh CJ Jr, Selik RM. The epidemiology of disseminated nontuberculous mycobacterial in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989; 139:4-7
6. Hawkins CC, Gold WM, Whimbey E, et al. Mycobacterium avium-complex infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986; 105: 184-188
7. Nightingale SD, Byrd LT, Southern PM, et al. Incidence of Mycobacterium avium-intracellulare in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165:1082-1085
8. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156:S1-S25
9. Griffith DE. Mycobacteria as pathogens of respiratory infection. Infect Dis North Am 1998; 12:593-611
10. Hocqueloux L, Lesprit P, Herrmann JL, et al. Pulmonary Mycobacterium avium complex disease without dissemination in HIV-infected patients. Chest 1998; 113:542-548
11. Lincoln EM, Gilbert LA. Disease in children due to mycobacteria other than Mycobacterium tuberculosis. Am Rev Respir Dis 1972; 105:683-714
12. O'Brien RJ, Geiter LJ, Snider DE Jr. The epidemiology of nontuberculous mycobacterial diseases in the United States. Am Rev Respir Dis 1987; 135:1007-1014
13. Horsburgh CR. Epidemiology of human disease caused by Mycobacterium avium complex. Can J Infect Dis 1994; 5:5B-9B
14. Elwood RK, Opazo AM, Lentini V, et al. Incidence of pulmonary disease caused by mycobacteria other than tuberculosis in British Columbia. Can Respir J 2002; 9:319-323
15. Kennedy MP, O'Connor TM, Ryan C, et al. Nontuberculous mycobacteria: incidence in Southwest Ireland from 1987 to 2000. Respir Med 2003; 97:257-263
16. Marras TK, Daley CL. Epidemiology of human pulmonary infection with nontuberculous mycobacteria nontuberculous. Clin Chest Med 2002; 23:553-567
17. Barker AF. Bronchiectasis. N Engl J Med 2002; 346:1383-1393
18. Angrill J, Agusti C, Torres A. Bronchiectasis. Curr Opin Infect Dis 2001; 14:193-197
19. Kilby JM, Gilligan PH, Yankaskas JR, et al. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 1992; 102:70-75
20. Oliver A, Maiz L, Canton R, et al. Nontuberculous mycobacteria in patients with cystic fibrosis. Clin Infect Dis 2001; 32:1298-1303
21. Ahn CH, Lowell JR, Onstad GD, et al. A demographic study of disease due to Mycobacterium kansasii or M intracellulare-avium in Texas. Chest 1979; 75:120-125
22. Trnka L, Dankova D, Svandova E. Six years' experience with the discontinuation of BCG vaccination: 4. Protective effect of BCG vaccination against the Mycobacterium avium intracellulare complex. Tuberc Lung Dis 1994; 75:348-352
23. Romanus V, Hallander HO, Wahlen P, et al. Atypical mycobacteria in extrapulmonary disease among children: incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage. Tuber Lung Dis 1995; 76:300-310
24. Vankayalapati R, Wizel B, Samten B, et al. Cytokine profiles in immunocompetent persons infected with Mycobacterium avium complex. J Infect Dis 2001; 183:478-484
25. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis 1990; 142:940-953
26. Corpe RF. Surgical management of pulmonary disease due to Mycobacterium avium-intracellulare. Rev Infect Dis 1981; 3:1064-1067
27. Moran JF, Alexander LG, Staub EW, et al. Long-term results of pulmonary resection for atypical mycobacterial disease. Ann Thorac Surg 1983; 35:597-604
28. Nelson KG, Griffith DE, Brown BA, et al. Results of operation in Mycobacterium avium-intracellulare lung disease. Ann Thorac Surg 1998; 66:325-330
29. Pomerantz M, Madsen L, Goble M, et al. Surgical management of resistant Mycobacterial tuberculosis and other mycobacterial pulmonary infections. Ann Thorac Surg 1991; 52:1108-1112
30. Shiriaishi Y, Nakajima Y, Takasuna K, et al. Surgery for Mycobacterium avium complex lung disease in the clarithromycin era. Eur J Cardiothorac Surg 2002; 21:314-318
31. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979; 119:107-159
32. Jenkins PA. Nontuberculous mycobacteria and disease. Eur J Respir Dis 1981; 62:69-71
33. Pinner M. Atypical acid-fast microorganisms. Am Rev Tuberc 1935; 32:424-439
34. Feldman WH, Davies R, Moses HE, et al. An unusual mycobacterium isolated from sputum of a man suffering from pulmonary disease of long duration. Am Rev Tuberc 1943; 48:82-93
35. Timpe A, Runyon EH. The relationship of "atypical" acid-fast bacteria to human disease: a preliminary report. J Lab Clin Med 1954; 44:202-209
36. Lewis AG Jr, Dunbar FP, Lasche EM, et al. Chronic pulmonary disease due to atypical mycobacterial infections. Am Rev Respir Dis 1959; 80:188-199
37. Reznikov M, Leggo JH. Investigation by seroagglutination of strains of the Mycobacterium intracellulare-M scrofulaceum group from house dusts and sputum in southeastern Queensland. Am Rev Respir Dis 1971; 104:951-953
38. Bhatia SVN. A study of mycobacterial species isolated from patients with chronic respiratory disease. Am Rev Respir Dis 1973; 108:378-381
39. Robakiewicz M, Grzybowski S. Epidemiologic aspects of nontuberculous mycobacterial disease and of tuberculosis in British Columbia. Am Rev Respir Dis 1974; 109:613-620
40. Goslee S, Wolinsky E. Water as a source of potentially pathogenic mycobacteria. Am Rev Respir Dis 1976; 113: 287-292
41. Meissner G, Anz W. Sources of Mycobacterium avium complex resulting in human diseases. Am Rev Respir Dis 1977; 116:1057-1064
42. Schaeffer WB. Incidence of the serotypes of Mycobacterium avium and atypical mycobacteria in human and animal diseases. Am Rev Respir Dis 1968; 97:18-23
43. Sriyabhaya N, Wongwatana S. Pulmonary infection caused by atypical mycobacteria in Thailand. Rev Infect Dis 1981; 3:1085-1089
44. Kleeberg HH. Epidemiology of mycobacteria other than tubercle bacilli in South Africa. Rev Infect Dis 1981; 3:1008-1012
45. Gorse GJ, Fairshter RD, Friedly G, et al. Nontuberculous mycobacterial disease: experience in a Southern California hospital. Arch Intern Med 1983; 143:225-228
46. Eaton T, Falkinham JO III, von Reyn CF. Recovery of Mycobacterium avium from cigarettes. J Clin Microbiol 1995; 33:2757-2758
47. Gruft H, Falkinham JO III, Parker BC. Recent experience in the epidemiology of disease caused by atypical mycobacteria. Rev Infect Dis 1981; 3:990-996
48. von Reyn CF, Maslow JN, Barber TW, et al. Persistent colonization of potable water as a source of Mycobacterium avium infection in AIDS. Lancet 1994; 343:1137-1141
49. du Moulin GC, Stottmeier KD, Pelletier PA, et al. Concentration of. Mycobacterium avium by hospital hot water systems. JAMA 1988; 260:1599-1601
50. Wendt SL, George KL, Parker BC, et al. Epidemiology of infection by nontuberculous mycobacteria: III. Isolation of potentially pathogenic mycobacteria from aerosols. Am Rev Respir Dis 1980; 122:259-263
51. Parker BC, Ford MA, Gruft H, et al. Epidemiology of infection by nontuberculous mycobacteria: IV. Preferential aerosolization of mycobacterium intracellulare from natural waters. Am Rev Respir Dis 1983; 128:652-656
52. O'Brien DP, Currie BJ, Krause VL, et al. Nontuberculous mycobacterial disease in Northern Australia: a case series and review of the literature. Clin Infect Dis 2000; 31:958-968
53. Hemphill RA, Morton JH. "Battey" disease in Dublin, Georgia. Am Rev Respir Dis 1969; 100:410-411
54. Woods GL, Washington JA II. Mycobacteria other than Mycobacterium tuberculosis: review of microbiologic and clinical aspects. Rev Infect Dis 1987; 9:275-294
55. Maesaki S, Kohno S, Koga H, et al. A clinical comparison between Mycobacterium avium and Mycobacterium intracellulare infections. Chest 1993; 104:1408-1411
56. Edwards LB, Palmer CE, Edwards PQ. Further studies of geographic variation in naturally acquired tuberculin sensitivity. Bull World Health Organ 1955; 22:63-83
57. Edwards LB, Comstock GW, Palmer CE. Contributions of Northern populations to the understanding of tuberculin sensitivity. Arch Environ Health 1968; 17:507-516
58. Palmer CE, Edwards PQ. Sensitivity of human populations to human and avian tuberculins. Bull World Health Organ 1955; 22:85-99
59. Edwards LB, Acquaviva FA, Livesay VT, et al. Atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in US. Am Rev Respir Dis 1969; 99(suppl):1-131
60. Christensen EE, Dietz GW, Ahn CH, et al. Pulmonary manifestations of Mycobacterium intracellularis. AJR Am J Roentgenol 1979; 133:59-66
61. Christensen EE, Dietz GW, Ahn CH, et al. Initial roentgenographic manifestations of pulmonary Mycobacterium tuberculosis, M kansasii, and M intracellularis infections Chest 1981; 80:132-136
62. Ahn CH, McLarty JW, Ahn SS, et al. Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare. Am Rev Respir Dis 1982; 125:388-391
63. Phillips S, Larkin JC Jr. Atypical pulmonary tuberculosis caused by unclassified mycobacteria. Ann Intern Med 1964; 60:401-408
64. Crow HE, King CT, Smith CE, et al. A limited clinical, pathologic, and epidemiologic study of patients with pulmonary lesions associated with atypical acid-fast bacilli in the sputum. Am Rev Respir Dis 1957; 75:199-222
65. Wijsmuller G, Erickson P. The reaction to PPD-Battey: a new look. Am Rev Respir Dis 1974; 109:29-40
66. Lewis AG Jr, Lasche EM, Armstrong AL, et al. A clinical study of the chronic lung disease due to nonphotochromogenic acid-fast bacilli. Ann Intern Med 1960; 53:273-285
67. Warring FC Jr. Mycobacteria in a New England hospital: a study of mycobacterial species occurring in the sputum of patients with chronic pulmonary disease. Am Rev Respir Dis 1968; 98:965-977
68. Bates JH. A study of pulmonary disease associated with mycobacteria other than Mycobacterium tuberculosis: clinical characteristics. Am Rev Respir Dis 1967; 96:1151-1156
69. Rosenzweig DY. Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex: clinical features and course in 100 consecutive cases. Chest 1979; 75:115-119
70. Stottmeier KD, Tose L, Jones C. Clinical and bacteriologic evaluation of pulmonary mycobacterioses in the greater Boston area. Am Rev Respir Dis 1973; 108:1227-1230
71. Ahn CH, Lowell JR, Onstad GD, et al. A demographic study of disease due to Mycobacterium kansasii or M intracellulare-avium in Texas. Chest 1979; 75:120-125
72. Good RC, Snider DE, Isolation of nontuberculous mycobacteria in the United States, 1980. J Infect Dis 1982; 146:829-833
73. Contreras MA, Cheung OT, Sanders DE, et al. Pulmonary infection with nontuberculous mycobacteria. Am Rev Respir Dis 1988; 137:149-152
74. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease: incidence, presentation, and response to therapy in a community setting. Am Rev Respir Dis 1991; 143:1381-1385
75. Cox JN, Brenner ER, Bryan CS. Changing patterns of mycobacterial disease at a teaching community hospital. Infect Control Hosp Epidemiol 1994; 15:513-515
76. Chapman JS. The atypical mycobacteria. Am Rev Respir Dis 1982; 125:119-124
77. Epstein MD, Aranda CP, Bonk S, et al. The significance of Mycobacterium avium complex cultivation in the sputum of patients with pulmonary tuberculosis. Chest 1997; 111:142-147
78. Beck F. Pulmonary disease due to atypical tubercle bacilli. Am Rev Respir Dis 1959; 80:738-743
79. Kubo K, Yamazaki Y, Hachiya T, et al. Mycobacterium avium-intracellulare pulmonary infection in patients without known predisposing pulmonary disease. Lung 1998; 176: 381-391
80. Obayashi Y, Fujita J, Suemitsu I, et al. Clinical features of non-tuberculous mycobacterial disease: comparisons between smear-positive and smear-negative cases, and between Mycobacterium avium and Mycobacterium intracellulare. Int J Tuberc Lung Dis 1998; 2:597-602
81. Embril J, Warren P, Yakrus M, et al. Pulmonary illness associated with exposure to Mycobacterium avium complex in hot tub water: hypersensitivity pneumonitis or infection? Chest 1997; 111:813-816
82. Case records of the Massachusetts General Hospital. Case 27-2000. N Engl J Med 2000; 343:642-649
83. Kahana LM, Kay JM, Yakrus MA, et al. Mycobacterium avium complex infection in an immunocompetent young adult related to hot tub exposure. Chest 1997; 111:242-245
84. Cappelluti E, Fraire AE, Schaefer OP. A case of "hot tub lung" due to Mycobacterium avium complex in an immunocompetent host. Arch Intern Med 2003; 163:845-848
85. Swensen SJ, Hartman TE, Williams DE. Computed tomographic diagnosis of Mycobacterium avium-intracellulare complex in patients with bronchiectasis. Chest 1994; 105: 49-52
86. Wittram C, Weisbrod GL. Mycobacterium avium complex lung disease in immunocompetent patients: radiography-CT correlation. Br J Radiol 2002; 75:340-344
87. Tanaka D, Niwatsukino H, Oyama T, et al. Progressing features of atypical mycobacterial infection in the lung on conventional and high resolution CT (HRCT) images. Radiat Med 2001; 19:237-245
88. Olivier KN. Nontuberculous mycobacterial pulmonary disease. Curr Opin Pulm Med 1998; 4:148-153
89. Tanaka E, Amitani R, Niimi A, et al. Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1997; 155:2041-2046
90. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. Chest 1992; 101:1605-1609
91. Maycher B, O'Connor R, Long R. Computed tomographic abnormalities in Mycobacterium avium complex lung disease include the mosaic pattern of reduced lung attenuation. Can Assoc Radiol J 2000; 51:93-102
92. Kubo K, Yamakazi Y, Masubuchi T, et al. Pulmonary infection with Mycobacterium avium-intracellulare leads to air trapping distal to the small airways. Am J Respir Crit Care Med 1998; 158:979-984
93. Primack SL, Logan PM, Hartman TE, et al. Pulmonary tuberculosis and Mycobacterium avium-intracellulare: a comparison of CT findings. Radiology 1995; 194:413-417
94. Lynch DA, Simone PM, Fox MA, et al. CT features of pulmonary Mycobacterium avium complex infection. J Comput Assist Tomogr 1995; 19:353-360
95. Obayashi Y, Fujita J, Suemitsu I, et al. Successive follow-up of chest computed tomography in patients with Mycobacterium avium-intracellulare complex. Respir Med 1999; 93: 11-15
96. Bates JH. Mycobacterium avium disease: progress at last. Am Rev Respir Dis 1986; 153:1737-1738
97. Rastogi N, Frehel C, Ryter A, et al. Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for the exclusion of antimicrobial agents? Antimicrob Agents Chemother 1981; 20:666-677
98. National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, Nocardia, and other aerobic actinomycetes. 2d. Tentative standard M24-T2. Wayne, PA: National Committee for Clinical Laboratory Standards, 2000
99. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS: AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994; 121:905-911
100. Woods GL. Susceptibility for mycobacteria. Clin Infect Dis 2000; 31:1209-1215
101. Jamal MA, Maeda S, Nakata N, et al. Molecular basis of clarithromycin-resistance in Mycobacterium avium intracellulare complex. Tuber Lung Dis 2000; 80:1-4
102. Wallace RJ Jr, Zhang Y, Brown BA, et al. Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med 1998; 158:1235-1244
103. Yamazaki Y, Kubo K, Takamizawa A, et al. Markers indicating deterioration of pulmonary Mycobacterium avium-intracellulare infection. Am J Respir Crit Care Med 1999; 160:1851-1855
104. DeGroote MA, Huitt G, Fulton K, et al. Retrospective analysis of aspiration risk and genetic predisposition in bronchiectasis patients with and without non-tuberculous mycobacteria infection [abstract]. Am J Respir Crit Care Med 2001; 163:A763
105. Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria: I. Multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167:828-834
106. Olivier KN, Weber DJ, Lee J-H, et al. Nontuberculous mycobacteria: II. Nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003; 167:835-840
107. Iseman MD, Buschman DL, Ackerson LM. Pectus excavatum and scoliosis: thoracic abnormalities associated with pulmonary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 1991; 144:914-916
108. Guide SV, Holland SM. Host susceptibility factors in mycobacterial infection: genetics and body morphotype. Infect Dis Clin North Am 2002; 16:163-186
109. Huang JH, Oefner PJ, Adi V, et al. Analyses of the NRAMP1 and IFN-γR1 genes in women with Mycobacterium avium-intracellulare pulmonary disease. Am J Respir Crit Care Med 1998; 157:377-381
110. Tanaka E, Kimoto T, Matsumoto H, et al. Familial pulmonary Mycobacterium avium complex disease. Am J Respir Crit Care Med 2000; 161:1643-1647
111. Watanabe K, Fujimura M, Kasahara K, et al. Characteristics of pulmonary Mycobacterium avium-intracellulare complex (MAC) infection in comparison with those of tuberculosis. Respir Med 2003; 97:654-659
112. Kubo K, Yamazaki Y, Hanaoka M, et al. Analysis of HLA antigens in Mycobacterium avium-intracellulare infection. Am J Respir Crit Care Med 2000; 161:1368-1371
113. Chakraborty AK, Damle PB, Davidson PT, et al. Disease due to Mycobacterium intracellulare: its possible association with human leukocyte antigens. Rev Infect Dis 1981; 3:1060-1063
114. Holland SM. Nontuberculous mycobacteria. Am J Med Sci 2001; 321:49-55
115. Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996; 335:1941-1949
116. Jouanguy E, Altare F, Lamhamedi S, et al. Interferon-γ-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 1996; 335:1956-1961
117. Dorman SE, Holland SM. Mutation in the signal-transducing chain of the interferon-γ receptor and susceptibility to mycobacterial infection. J Clin Invest 1998; 101:2364-2369
118. Holland SM. Immune deficiency presenting as mycobacterial infection. Clin Rev Immunol 2001; 20:121-137
119. Dorman SE, Holland SM. Interferon-γ and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev 2000; 11:321-333
120. Jouanguy E, Lamhamedi-Cherradi S, Lammas D, et al. A human IFNγR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet 1999; 21:370-378
121. Holland SM. Immunotherapy of mycobacterial infections. Semin Respir Infect 2001; 16:47-59
122. Shirasuchi H, Ellner JJ. Expression of IL-18 by Mycobacterium avium-infected human monocytes: association with M avium virulence. Clin Exp Immunol 2001; 123:203-209
123. Doherty TM, Sher A. IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J Immunol 1998; 160:5428-5435
124. Holland SM, Dorman SE, Kwon A, et al. Abnormal regulation of interferon-γ, interleukin-12, and tumor necrosis factor-α in human interferon-γ receptor 1 deficiency. J Infect Dis 1998; 178:1095-1104
125. Dupuis S, Dargemont C, Fieschi C, et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 2001; 293:300-303
126. Holland SM, Eisenstein EM, Kulms DB, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferonγ: a preliminary report. N Engl J Med 1994; 330:1348-1355
127. Chatte G, Panteix G, Perrin-Fayolle M, et al. Aerosolized interferon gamma for Mycobacterium avium-complex disease. Am J Respir Crit Care Med 1995; 152:1094-1096
128. Bermudez LE, Inderlird C, Young LS. Stimulation with cytokines enhances penetration of azithromycin in human macrophages. Antimicrob Agents Chemother 1991; 35:2625-2629
129. Gomez-Flores R, Tucker SD, Kansal R, et al. Enhancement of antibacterial activity of clofazimine against Mycobacterium avium-Mycobacterium intracellulare complex infection induced by IFNγ is mediated by TNFα. J Antimicrob Chemother 1997; 39:189-197
130. Safdar A, White DA, Stover D, et al. Profound interferonγ deficiency in patients with chronic pulmonary nontuberculous mycobacteriosis. Am J Med 2002; 113:756-759
131. Fischer DA, Lester W, Schaeffer WB. Infections with typical mycobacteria: five years' experience at the National Jewish Hospital. Am Rev Respir Dis 1968; 98:29-34
132. Yeagher H Jr, Raleigh JW. Pulmonary disease due to Mycobacterium intracellulare. Am Rev Respir Dis 1973; 108:547-552
133. Tsukumura M, Shimoide H, Segawa J, et al. Clinical feature of lung disease due to Mycobacterium intracellulare. Kekkaku 1974; 49:139-145
134. Dutt AK, Stead WW. Long-term results of medical treatment in Mycobacterium intracellulare infection. Am J Med 1979; 67:449-453
135. Seibert AF, Bass JB. Four drug therapy of pulmonary disease due to Mycobacterium-avium complex [abstract]. Am Rev Respir Dis 1979; 119:A399
136. Davidson PT, Khanijo V, Goble M, et al. Treatment of disease due to Mycobacterium intracellulare. Rev Infect Dis 1981; 3:1052-1059
137. Hunter AM, Campbell IA, Jenkins PA, et al. Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex. Thorax 1981; 36: 326-329
138. Engbaek HC, Vergmann B, Bentzon MW. Lung disease caused by Mycobacterium avium/Mycobacterium intracellulare. Eur J Respir Dis 1981; 62:72-83
139. Engbaek HC, Vergmann B, Bentzon MW. A prospective study of lung disease caused by Mycobacterium avium/Mycobacterium intracellulare. Eur J Respir Dis 1984; 65: 411-418
140. Ahn CH, Ahn SS, Anderson RA, et al. A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 1986; 134:438-441
141. Etzkorn ET, Aldarondo S, Mc Allister CK, et al. Medical therapy of Mycobacterium avium-intracellulare pulmonary disease. Am Rev Respir Dis 1986; 134:442-445
142. Horsburgh CR, Mason UG III, Heifets LB, et al. Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing. Am Rev Respir Dis 1987; 135:418-421
143. Tsukamura M. Evidence that antituberculous drugs are really effective in the treatment of pulmonary infection caused by Mycobacterium avium complex. Am Rev Respir Dis 1988; 137:144-148
144. Heurlin N, Petrini B. Treatment of non-tuberculous mycobacterial infections in patients without AIDS. Scand J Infect Dis 1993; 25:619-623
145. Tsukamura M, Ichiyama S, Miyauchi T. Superiority of enviomycin or streptomycin over ethambutol in initial treatment of lung disease caused by Mycobacterium avium complex. Chest 1989; 95:1056-1058
146. Research committee of the British Thoracic Society. First randomized trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001; 56:167-172
147. The research committee of the BTS. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment. Int J Tuberc Lung Dis 2002; 6:628-634
148. Wallace RJ Jr, Brown BA, Griffith DE, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994; 149:1335-1341
149. Wallace RJ Jr, Brown BA, Griffith DE, et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex. Am J Respir Crit Care Med 1996; 153:1766-1772
150. Griffith DE, Brown BA, Girard WM, et al. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis 1996; 23:983-989
151. Griffith DE, Brown BA, Murphy DT, et al. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. J Infect Dis 1998; 178:121-126
152. Griffith DE, Brown BA, Cegielski P, et al. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000; 30:288-292
153. Griffith DE, Brown BA, Girard WM, et al. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 2001; 32:1547-1553
154. Dautzenberg B, Piperno P, Diot P, et al. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest 1995; 107:1035-1040
155. Roussel G, Igual J. Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM: Groupe d'Etude et de Traitment des Infections a Mycobacteries. Int J Tuberc Lung Dis 1998; 2:462-470
156. Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium, avium complex pulmonary disease. Am J Respir Crit Care Med 1999; 160:866-872
157. Huang JH, Kao PN, Adi V, et al. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest 1999; 115:1033-1040
158. Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003; 124:1482-1486
159. Kennedy TP, Weber DJ. Nontuberculous mycobacteria: an underappreciated cause of geriatric lung disease. Am J Respir Crit Care Med 1994; 149:1654-1658
160. Heifets LB. Synergistic effect of rifampin, streptomycin, ethionamide, and ethambutol on Mycobacterium intracellulare. Am Rev Respir Dis 1982; 125:43-48
161. Bates JB Jr. Mycobacterium avium-intracellulare: rational therapy of chronic pulmonary infection? Am Rev Respir Dis 1986; 134:431-432
162. Anderson R, Joone G, van Rensburg CEJ. An in vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrob Chemother 1988; 22:923-933
163. Brown BA, Wallace RJ Jr, Onyi GO. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother 1992; 36:1987-1990
164. Olsen KM, San Pedro GS, Gann LP, et al. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother 1996; 40:2582-2585
165. Baldwin DR, Wise R, Andrews JM, et al. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 1990; 3:886-890
166. Gladue RP, Bright GM, Isaacson RE, et al. In vitro and in vivo uptake of azithromycin (CP-62, 993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989; 33:277-282
167. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335:384-391
168. Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin; Canadian HIV Trails Network Protocol 010 Study Group. N Engl J Med 1996; 335:377-383
169. Horsburgh CR Jr. Advances in the prevention and treatment of Mycobacterium avium disease. N Engl J Med 1996; 335:428-430
170. Nash KA. Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium. Antimicrob Agents Chemother 2001; 45:1607-1614
171. Wallace RJ Jr, Brown BA, Griffith DE. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993; 16:215-221
172. Griffith DE, Brown BA, Girard WM, et al. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995; 21:594-598
173. Apseloff G, Foulds G, Laboy-Goral L, et al. Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers. J Clin Pharmacol 1998; 38:830-835
174. Gioulekas J, Hall A. Uveitis associated with rifabutin therapy. Aust N Z J Ophthalmol 1995; 23:319-321
175. Le Gars L, Collon T, Picard O, et al. Polyarthralgia-arthritis syndrome induced by low doses of rifabutin. J Rheumatol 1998; 26:1201-1202
176. Griffith DE, Brown BA, Wallace RJ Jr. Varying doses of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus-negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. Clin Infect Dis 1996; 23:1321-1322
177. Wallace RJ Jr, Brown BA, Griffith DE, et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M intracellulare infection. J Infect Dis 1995; 171: 747-750
178. Brown BA, Griffith DE, Girard W, et al. Relationship of adverse effects to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin Infect Dis 1997; 24:958-964
179. Rodriguez Diaz JC, Lopez M, Ruiz M, et al. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents 2003; 21:585-588
180. Vesterhus P, Holland SM, Abrahamsen TG, et al. Familial disseminated infection due to atypical mycobacteria with childhood onset. Clin Infect Dis 1998; 27:822-825
181. Murray HW. Interferon-γ, the activated macrophage, and host defense against microbial challenge. Ann Intern Med 1988; 108:595-608